Licensing opportunity
Researchers at the University of Edinburgh have produced rabbit polyclonal antibodies raised against the chromatin-binding domains of the human Lamin proteins A/C, B1 and B2 that they say give strong signals with low background and are, therefore, ideal for immunofluorescence applications.
Most currently available antibodies to Lamin proteins are made against non-ideal epitopes. They are either to the Rod domain, which is highly conserved (the antibodies lack specificity among subtypes), or they are to the C terminal globular domain region of the proteins, a region which has multiple binding partners and is therefore often masked.
The new antibodies have been made to the chromatin binding region of the Lamin proteins, a region which is the least masked at the nuclear envelope. Consequently, they are highly specific and give clear strong signals in immunofluorescence applications.
The antibodies recognise all splice variants of their respective Lamin genes.
Edinburgh University is looking for commercial organisations to in-licence the technology to sell the polyclonal antibody for research purposes. This technology is available to license under a standard non-exclusive license agreement.
For more information, visit the project’s page at: http://www.university-technology.com/details/polyclonal-antibodies-to-lamins
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
Follow where the public and private R&I money is going and which collaborative opportunities you can pursue.
